IgA nephropathy (IgAN) is the most common form of glomerulonephritis and a principal cause of end-stage renal disease (ESRD) throughout the world. 1 Selectins are cell-to-cell adhesion molecules involved in the leukocyteendothelial cell interaction leading to leukocytic infiltration into tissue. 2 Leukocytic infiltration into the glomerulus and renal interstitium appears to be critical for the pathogenesis of IgAN.
G-CSF is widely used to induce neutrophil production after myelosuppressive treatment and to mobilize BM hematopoietic progenitors that are provided for hematopoietic stem cell transplantation (HSCT) recipients. Although G-CSF is normally well-tolerated, it has been associated with rare but serious toxicities including splenic rupture, allergic reactions, flares of underlying autoimmune disorders and vascular complications, 3, 4 as previously reviewed by Tigue et al., 5 as well as hematological malignancies. 6 G-CSF induces E-selectin expression on endothelial cells 7 and E-selectin ligand (CD44) expression on mobilized, circulating leukocytes. 8 Therefore, enhanced leukocyteendothelial cell interactions due to the upregulation of both E-selectin and CD44 may be crucial in the pathobiology of G-CSF-associated vascular complications. This report describes a previously healthy 7-year-old boy who developed IgAN after the administration of G-CSF.
A 7-year-old boy was admitted to hospital to serve as a donor for his sister with juvenile myelomonocytic leukemia and who was scheduled to undergo peripheral blood SCT. He had no significant medical history. He had undergone regular health checkups at school, including urinalysis 3 months before admission in hospital, and all findings had been normal. There was no renal disorder among his family and relatives. He was administered 300 mg (12.5 mg/kg) filgrastim (GRAN; Kyowa Hakko Kirin Co. Ltd., Tokyo, Japan) on days 1-3 once daily, and 375 mg (15.6 mg/kg) twice on day 4 s.c. On day 5, he was administered the final dose (375 mg) of filgrastim and thereafter underwent leukapheresis without any adverse reactions. He was discharged shortly after completion of the procedure.
At 13 days after the first dose of filgrastim, he presented with general fatigue. Physical examination showed no abnormality. His blood pressure was normal and he had no fever. Hematological examination was normal. The blood urea nitrogen was 13.8 mg per 100 ml, serum creatinine 40.7 mmol/l and creatinine clearance 51 ml/min. Serological tests for antinuclear antibody were negative. Levels of serum complement factors C3 and C4 were normal. Concentrations (normal ranges) of the serum IgG, IgA and IgM were 776 (670-1560), 134 (48-276) and 146 (85-337) mg per 100 ml, respectively. Urinalysis revealed hematuria (1 þ ) and proteinuria (3 þ ). The boy underwent kidney biopsy 33 days after the first dose of filgrastim, because of persistent hematuria and proteinuria. Histological studies revealed prominent IgA deposition on the mesangium with mesangial and endocapillary proliferation, compatible with the acute phase of IgAN. He was treated with a combination of prednisolone, azathioprine, warfarin and dipyridamole on day 75 after the first dose of filgrastim because his urinary findings remained abnormal. He responded to the treatment quickly, and his urinalysis normalized by day 99. It remained normal until the most recent visit, 462 days after the first dose of filgrastim.
Indirect immunofluorescence staining was performed using monoclonal antibodies P2H3 and DF1485 against E-selectin and CD44, respectively (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA). Expression of E-selectin in the glomerulus was evident in this patient (Figure 1a ), but not in any other patient with IgAN who had not received filgrastim (Figure 1b) or a control (data not shown). Furthermore, CD44 expression was also shown in the glomerulus of the patient, but not in the control (data not shown).
G-CSF has a number of biological functions, thus fulfilling several clinical roles. Notably, it has been administered to many healthy individuals who have served as donors for HSCT; therefore, tolerance issues regarding its administration are crucial. It is very important to report severe toxicities developing in PBSC donors who have received G-CSF, especially in the case of children. 6 Reported adverse effects include bone pain, headache or general fatigue after G-CSF administration in approximately 30% of all cases.
9 Furthermore, although rare, vasculitic complications, such as coronary artery disease and capillary leak syndrome may occur, as well as hematological malignancies. [3] [4] [5] [6] IgA nephropathy, initially considered to be benign, leads to end-stage renal failure within 20 years in approximately 40% of patients. 1 This report suggests that G-CSF administration might be linked to IgAN in a previously healthy donor, based on the chronological sequence and the recent findings that G-CSF induces the expression of E-selectin 7 and its ligand, 8 which are the key factors involved in the pathogenesis of IgAN. It should be also noted that the donor was administered a relatively high dose of G-CSF (31.2 mg/kg/day on day 4), because of the critical clinical condition of the recipient. This suggests that the donor in the current case may have been genetically susceptible to IgAN and thus the administration of high dose of G-CSF may have induced the subsequent development of IgAN. Although IgAN has never been previously considered to be an adverse effect of G-CSF, and it is not possible to prove this hypothesis experimentally, it is nevertheless important to note that G-CSF administration may cause IgAN, a principal cause of ESRD worldwide, in susceptible individuals.
It should be noted that selectin gene polymorphisms have been suspected to have a role in the development and/or progression of IgAN. 9 The establishment of a method(s) to screen and identify individuals genetically susceptible to IgAN and other vascular events may help avoid this rare but serious complication of G-CSF in susceptible donors. Furthermore, genetic susceptibility may account for the increased risk of myelodysplastic syndrome or other G-CSF-related toxicities among breast cancer patients receiving G-CSF. 10 Collection and analysis of cases are required.
Finally, although G-CSF should not be assumed to be risk free, its benefits still outweigh the risks. Extensive investigation into its safety and toxicity, particularly in the pediatric population, is essential.
